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Abstract 
Background:  In the Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes 
in non-ST elevation myocardial infarction (FAMOUS) clinical trial, FFR was shown to significantly reduce coronary 
revascularisation, compared to visual interpretation of standard coronary angiography without FFR. We estimated the 
cost-effectiveness from a UK National Health Service perspective, based on the results of FAMOUS.
Methods: A mixed trial- and model-based approach using decision and statistical modelling was used. Within-trial 
(1-year) costs and QALYs were assembled at the individual level and then modelled on subsequent management 
strategy [coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI) or medical therapy (MT)] 
and major adverse coronary events (death, MI, stroke and revascularisation). One-year resource uses included: mate-
rial, hospitalisation, medical, health professional service use and events. Utilities were derived from individual EQ5D 
responses. Unit costs were derived from the literature. Outcomes were extended to a lifetime on the basis of MACE 
during the 1st year. Costs and QALYs were modelled using generalized linear models whilst MACE was modelled 
using logistic regression. The analysis adopted a payer perspective. Costs and outcomes were discounted at 3.5 %.
Results: Costs were related to the subsequent management strategy and MACE whilst QALYs were not. FFR led to 
a modest cost increase, albeit an imprecise increase, over both the trial [£112 (−£129 to £357)] and lifetime horizons 
[£133 (−£199 to £499)]. FFR led to a small, albeit imprecise, increase in QALYs over both the trial [0.02 (−0.03 to 0.06)] 
and lifetime horizons [0.03 (−0.21 to 0.28)]. The mean ICER was £7516/QALY and £4290/QALY over the trial and life-
time horizons, respectively. Decision remained high; FFR had 64 and 59 % probability of cost-effectiveness over trial 
and lifetime horizons, respectively.
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Background
Non-ST segment elevation myocardial infarction 
(NSTEMI) is the most common form of acute coronary 
syndromes (ACS) [1]. The decision for coronary revascu-
larisation is currently guided by visual interpretation of 
a coronary angiogram [1–3]. Visual interpretation, how-
ever, is subjective, potentially inaccurate and a cause for 
misdiagnosis and incorrect treatment decisions [4–6].
Myocardial FFR (FFRmyo) is defined as the maxi-
mal blood flow to the subtended myocardium in the 
presence of a stenosis, compared to maximum flow in 
the absence of a stenosis. An FFR ≤  0.80 is correlated 
with the presence of inducible ischemia whereas an 
FFR  ≥  0.80 indicates patients can be managed safely 
with medical therapy (MT) [7]. Recent studies have 
demonstrated the value of fractional flow reserve (FFR) 
in guiding treatment decisions [8–13]. The actual 
impact of FFR on prospective management strategies 
has only recently been explored [10]. In addition, it is 
in patients with unstable coronary artery disease, par-
ticularly NSTEMI, who are managed by an invasive 
treatment strategy where FFR may prove to be clinically 
most useful.
The Fractional flow reserve versus Angiography 
in guiding Management to Optimise oUtcomeS in 
Non-ST-segment Elevation Myocardial Infarction 
(FAMOUS—NSTEMI, here referred to as ‘FAMOUS’) 
(NCT02073422) was a randomised multicentre pilot trial 
designed to evaluate impact of FFR vs. coronary angiog-
raphy without FFR on subsequent management strategy 
[14] including either percutaneous coronary interven-
tion (PCI), coronary artery bypass graft (CABG) or MT. 
FAMOUS had a follow-up of 1 year. When FFR results 
were disclosed in the FFR-guided group, the management 
strategy changed in 21.6 % of patients and resulted in a 
higher proportion of management with MT compared to 
the coronary angiography-guided group.
As FFR is a diagnostic test, the true value of FFR relates 
to its impact on patient management and outcomes [15–
17]. This study focuses on the outcomes following patient 
management both within and beyond the trial time 
period. The aim of this study was to evaluate the cost-
effectiveness of FFR compared with standard coronary 
angiography in patients with NSTEMI.
Methods
This study expands on the 1-year clinical results of 
FAMOUS [14] by considering the cost-effectiveness. We 
used a mixed model- and trial-based approach with deci-
sion and statistical modelling. Decision modelling can 
present patient outcomes as part of the clinical pathway 
[18, 19]; statistical modelling can identify and reduce 
heterogeneity [20]. This can be especially important if 
trial endpoints are then used to estimate final economic 
endpoints.
The base population was patients with recent NSTEMI 
(mean 62  years old). The comparators were FFR-guided 
management and standard angiography-guided man-
agement. Economic outcomes were costs and quality-
adjusted life-years (QALYs). Outcomes were viewed from 
a single health payer perspective—namely, the National 
Health Service (NHS). The analysis was conducted for 
both the 1-year trial time horizon as well as a lifetime 
horizon.
Model
The decision problem is summarised by the follow-
ing decision analytic model, which was adapted from 
a previous design [21] (Fig.  1). Health and cost conse-
quences were modelled on the treatment decision (MT, 
PCI or CABG) because treatment decision was directly 
informed by FFR or standard angiography. Outcomes 
were modelled additionally on incident major adverse 
cardiovascular outcomes (MACE) (death, myocardial 
infarction, stroke and revascularisation) because MACE 
served as the intermediate endpoint to model life expec-
tancy beyond the trial time horizon, a common practice 
in previous models [2, 21]. Following the index year, a 
common QALY and cost tariff was applied to all years, 
dependent on the presence of MACE during the index 
year.
Parameter sources
The probability of MT, PCI or CABG as well as the prob-
ability of MACE following each respectively was derived 
from the FAMOUS study. The life expectancy beyond 1 
year following MACE was derived from a previous model 
in patients with unstable angina or NSTEMI [2, 21].
Trial period resource use was obtained from FAMOUS 
and unit costs were obtained from the literature. Individ-
ual level costs were assembled by multiplying resource use 
with unit costs. Resource use included: the pressure wire 
intervention; the treatment strategy (PCI, CABG or medi-
cal management); catheterisation laboratory time; Coro-
nary Care Unit (CCU), Intensive Treatment Unit (ITU) 
and general ward days; other in-hospital procedures 
Conclusions: FFR was cost-effective at the mean, albeit with considerable decision uncertainty. Uncertainty can be 
reduced with more information on long-term health events.
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(x-rays and echocardiograms) and health events (rehos-
pitalisation, revascularisation, myocardial infarction, and 
stroke). Regarding the treatment strategy, the analysis 
included use of PCI materials (catheters, balloons and 
stents) and drugs (glycoprotein IIa/IIIb inhibitors, bivali-
rudin, clopidogrel). The use of a pressure wire in patients 
randomised to coronary angiography alone was removed 
from the cost estimates as it was protocol driven. Unit cost 
information was generally derived from national sources, 
including NHS Reference Costs, the British National For-
mulary (http://www.bnf.org), Information Services Divi-
sion Scotland [22] and NICE Clinical Guidelines [2]. Unit 
cost parameter information is presented in Table 1.
Long-term annual disease costs for those with and 
without MACE were derived from a previous model of 
FFR in NSTEMI patients [21].
Trial period QALYs were obtained from FAMOUS 
by integrating the area under the curve of health utili-
ties. Health utilities at presentation, 6 months and 1 year 
were estimated with the EuroQol 5D-3L instrument. 
Responses were converted into utilities with the use of 
a UK-specific algorithm [23]. For the long-term exten-
sion, the utility of those without MACE followed the 
general population and declined with increasing age in 
the model. The mean utility change (decrement) of those 
with MACE was estimated to be −0.05 [21, 24].
Analysis
We planned to model one-year trial costs and QALYs 
on the treatment decision (MT, PCI or CABG) and inci-
dent MACE. To estimate the cost parameters, we derived 
adjusted cost estimates fitting a generalized linear model 
(GLM) and performing marginal prediction. GLM is 
the appropriate method when the objective is to obtain 
efficient estimation of skewed variables [20, 25–27]. Appro-
priate family and link functions were determined using the 
Modified Park’s and Hosmer and Lemeshow tests, respec-
tively. The regression included a treatment term in addi-
tion to other relevant baseline characteristics, selected by a 
combination of clinical reasoning, independent association 
with the dependent variable at the p < 0.25 level and preva-
lence >10 %. The final form of the cost model included the 
following additional covariates: utility at presentation, age, 
sex, smoking status and history of PCI. The final form of 
the QALYs model included the following additional covari-
ates: utility at presentation, age, sex and smoking status.
Estimation of MACE following treatment decision 
(MT, PCI or CABG) was derived in a similar man-
ner. The final form of the model included the following 
covariates: utility at presentation, age, sex and history of 
chronic obstructive pulmonary disease. A logistic regres-
sion was used to regress MACE on treatment decision, 
along with baseline characteristics. The ORs for PCI and 
CABG were then extracted and applied to a baseline MT, 
which was estimated using marginal prediction. ORs 
were applied to odds [risk/(1-risk)] and converted to risks 
(odds/(1 + odds)) in the model.
We first tested the significance of the model struc-
ture using analysis of variance tests. Partial analysis of 
variance tests were conducted using deviances from an 
ANOVA and a p value using the Chi-Squared distribu-
tion. If the model structure in Fig.  1 showed no incre-
mental value, raw trial estimates were used.
The developed statistical models were then used to esti-
mate outcomes using marginal prediction. Any observed 
comparison of two groups, whether randomised or 
not, is likely to show imbalance in baseline covariates, 
regardless of statistical significance. Marginal prediction 
effectively holds all else equal, save for the predictor of 
interest—treatment.
Missing data was imputed using multiple imputation 
with chained equations (MICE), where appropriate [28].
We used bootstrapping and probabilistic sensitivity 
analysis to incorporate sampling uncertainty, parameter 
uncertainty and model uncertainty. Beta, gamma and 
lognormal distributions were generally used for utility, 
cost and relative risk parameters. A dirichlet distribution 
was used to randomly sample >2 rival events, such as the 
treatment management decision of MT, PCI or CABG. 
We conducted model selection in Stata 12, statistical 
modelling in R 3.2 [29] and decision analytic modelling 
in Microsoft Excel. All costs are presented in 2014 British 
Pound Sterling.
Research ethics
The trial was approved by the National Research Ethics 
Service (reference 11/S0703/6) and complies with the 
Fig. 1 Model structure showing subsequent management strategy 
and MACE. Model structure is the same for angiography
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Table 1 Data inputs used in the model
Mean SE Distribution Source
Treatment decision probabilities
 MT, FFR 0.23 0.03 Dirichlet FAMOUS
 PCI, FFR 0.71 0.02 Dirichlet FAMOUS
 CABG, FFR 0.06 0.02 Dirichlet FAMOUS
 MT, standard care 0.13 0.02 Dirichlet FAMOUS
 PCI, standard care 0.80 0.01 Dirichlet FAMOUS
 CABG, standard care 0.07 0.02 Dirichlet FAMOUS
Equipment costs (£):
 Guiding catheter 20 0 – National procurement
 Guidewire 20 0 – National procurement
 Pressure wire 270 0 – National procurement
 Adenosine vial 12 0 – BNF
 Balloon catheter 50 0 – National procurement
 Drug eluting stent 290 0 – National procurement
 Bare metal stent 90 0 – National procurement
 Tirofiban (avg/patient) 242 69 Gamma BNF; evidence.nhs.uk
 Bivalirudin (avg/patient) 625 48 Gamma BNF; evidence.nhs.uk
 Clopidogrel (per month) 2 – BNF; evidence.nhs.uk
Procedure costs (£):
 CABG 5041 313 Gamma NHS reference costs
 Echocardiogram 128 26 Gamma Golden Jubilee National Hospital
 Optical coherence tomography 1020 204 Gamma Golden Jubilee National Hospital
 Intravascular ultrasound 540 108 Gamma Golden Jubilee National Hospital
 Chest x-ray 18 4 Gamma Golden Jubilee National Hospital
Hospitalisation costs (£):
 Cath lab time (per hour) 1681 301 Gamma ISD Scotland
 Day in CCU 1492 60 Gamma Golden Jubilee National Hospital
 Day in ITU 2288 458 Gamma Golden Jubilee National Hospital
 Day in general ward 303 17 Gamma NHS reference costs
Inhospital event costs (£):
 Severe bleeding 222 3 Gamma NHS reference costs
 Stroke 2709 129 Gamma NHS reference costs
 MI 1492 76 Gamma NHS reference costs
Event costs (£):
 Rehospitalisation 2261 452 Gamma NICE CG94
 Revascularisation 2477 63 Gamma NHS reference costs
 MI 2261 452 Gamma NICE CG94
Disease related costs (index year) (£):
 Index year after additional MI 3228 215 Gamma NICE CG94
 Index year of stroke 16,926 428 Gamma NICE CG68
Additional life-expectancies (years)
 MACE 10.70 2.20 Normal Kent et al., NICE CG94
 No MACE 5.96 1.30 Normal Kent et al., NICE CG94
Other long-term parameters
 Annual cost post year 1 (£) 423 55 Gamma Kent et al., NHS reference costs
 MACE utility change −0.05 0.04 Beta Kent et al., Palmer et al.
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Declaration of Helsinki. The study information sheet that 
had been approved by the research ethics committee was 
provided to each participant. Written informed consent 
was obtained before the diagnostic coronary angiogram 
and randomization.
Results
Unadjusted trial outcomes
EQ-5D-3L responses were missing in 17 and 24  % of 
the trial population at 6- and 12-months, respectively. 
However, baseline characteristics were balanced across 
missing and complete groups (Additional file 1); as well, 
missingness was not statistically associated with inter-
vention (Chi-squared test; χ2 = 0.0234; df = 1, p = 0.88). 
Missing at random was thus a plausible conclusion and 
multiple imputation was subsequently conducted (Addi-
tional file 1).
Following FFR, patients received MT, PCI and CABG 
with probabilities of 23, 71 and 6 %, respectively. Follow-
ing standard angiography, patients received MT, PCI and 
CABG with probabilities of 13, 80 and 7 %, respectively.
Utilities and resource use—unadjusted—for the trial 
population are tabulated in the Additional file  1. Com-
pared to the standard care group, the utilities in the 
FFR group were lower at presentation (0.78 vs 0.80) but 
comparable by 6-months (0.83 vs 0.83) and higher at 
12-months of follow-up (0.83 vs. 0.80), although none of 
the differences were significant (Additional file 1).
FFR measurement required an average of 1.03 pressure 
wires. Lower revascularisation meant lower use of PCI 
materials such as balloon catheters, drug eluting stents 
and bare metal stents. Following management with FFR, 
use of echocardiography was higher whilst OCT and 
x-rays were no different to standard care. Patients man-
aged with FFR passed similar amounts of time in the 
catheter laboratory but less ITU time and general ward 
time. For incident events following treatment, the FFR 
group had slightly lower rates of rehospitalisation and 
MI whilst having similar rates of revascularisation, stroke 
and death compared to standard care; however event 
rates were extremely low in some and none displayed sta-
tistical significance (Additional file 1).
Unadjusted, raw mean costs and QALYs are presented 
in Table  2. FFR measurement led to increased costs of 
pressure wire use (+£279) and cath lab time (+£57) 
which was offset modestly by savings in PCI (−£92), 
CABG (−£32) and medication use (−£17). However, the 
largest cost savings following FFR were in reduced hospi-
tal length of stay (−£331) and index year events (−£243) 
but they also displayed the greatest uncertainty. Overall, 
there was a mean cost saving of £349 and an incremental 
0.02 QALYs following FFR during the 1st year.
Statistical models
Results of the statistical models are provided in the Addi-
tional file 1. Modelling cost on the treatment decision inter-
acted with MACE and displayed statistical significance 
under a partial analysis of deviance test (p < 0.001); mod-
elling MACE on the treatment decision trended towards 
statistical significance (p = 0.07). For QALYs, however, the 
addition of treatment decision interacted with MACE did 
not improve the model (p = 0.37). The model structure in 
Fig. 1 was thus used for the estimation of cost and MACE 
whilst it was not imposed for QALYs; instead, unadjusted 
raw QALYs were used for the trial period.
Table  3 presents the adjusted estimates from the sta-
tistical models. As expected, 1-year costs were higher in 
the presence of MACE vs. no MACE. MT represented 
the lowest cost, followed by PCI and CABG. Table 3 also 
presents the extracted odds-ratios of MACE for PCI and 
Table 2 Raw unadjusted total and incremental costs and QALYs following standard care and FFR management
Standard care FFR Difference
Mean (95 % CI) Mean (95 % CI) Mean (95 % CI)
Cost (£)
 Pressure wire 0 (0–0) 279 (273–287) 279 (273–287)
 PCI 837 (750–932) 766 (689–844) −72 (−193 to 45)
 CABG 346 (174–550) 314 (143–487) −32 (−292 to 226)
 Medications 59 (48–71) 49 (38–60) −17 (−42 to 7)
 Cath lab time 1806 (1672–1949) 1864 (1770–1962) 57 (−114 to 221)
 Length of stay 4435 (4043–4847) 4104 (3595–4673) −331 (−1002 to 356)
 Other procedures 125 (117–132) 134 (127–141) 9 (−1 to 20)
 Events during index year 956 (613–1372) 713 (468–982) −243 (−736 to 200)
Total cost (£) 8565 (7872–9304) 8222 (7518–8985) −349 (−1367 to 675)
Total QALYs 0.801 (0.765–0.835) 0.82 (0.787–0.845) 0.02 (−0.029 to 0.061)
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CABG and the marginal predicted probability of MACE 
following MT. Compared to MT, PCI did not increase the 
odds of MACE appreciably, whilst CABG increased the 
odds over threefold.
Cost‑effectiveness
Mean results of the cost-effectiveness analysis are pre-
sented for both the one-year trial and lifetime time hori-
zons (Table  4). FFR led to a mean additional £112 and 
0.01 QALYs over the trial time horizon, compared to 
standard angiography, whilst over a lifetime it led to an 
additional £133 and 0.03 QALYs. The mean ICERs were 
£7516/QALY and £4290/QALY over the trial and lifetime 
horizons, respectively.
The cost-effectiveness plane displays the variability in 
incremental costs and QALYs (Fig. 2). Variability in both 
incremental costs and QALYs was considerably greater 
under the lifetime horizon, compared to the trial time 
horizon. Both time horizons presented consistent results 
of increased costs against a background of compara-
ble QALYs. This relative comparability in incremental 
QALYs presents itself more clearly in the cost-effective-
ness acceptability curve (CEAC) (Fig. 3). The cost-effec-
tiveness of FFR remained relatively uncertain throughout 
the willingness-to-pay (WTP) range of £20,000–£30,000/
QALY for both the trial time horizon (64–67 %) and the 
lifetime horizon (~59 %) (Fig. 3).
Discussion
Our analysis presents an early estimate of the combined 
health and economic impact of FFR-guided management 
in patients with NSTEMI as measured by FAMOUS. 
Both the trial and lifetime horizons present consistent 
results of a modest, relatively precise incremental cost 
(£112 and £133, respectively) along with modest, albeit 
imprecise, incremental QALYs (0.01 and 0.03, respec-
tively). FFR displays an acceptable ICER of £4290/QALY. 
However, decision uncertainty remains considerable.
The strength of the present analysis is its use of trial 
data to reduce heterogeneity in economic outcomes 
through the use of statistical modelling and marginal 
prediction. Statistical modelling identified the sources of 
heterogeneity and distilled the attributable effect of the 
treatment management (MT, PCI and CABG) along with 
MACE; one related to the critical decision in the patient 
management pathway whilst the other related to the 
critical patient outcomes. Marginal prediction improved 
estimation of economic outcomes by reducing heteroge-
neity unrelated to the patient management pathway and 
critical patient outcomes.
The present results highlight the impact of modelling 
for within-trial assessments. The impact statistical mod-
elling and marginal prediction on the variability was 
Table 3 Statistical model outputs used in  the decision 
analytic model
a 95 % confidence interval
Mean SE
Decision model costs (£)
 MT, MACE 9622 864
 PCI, MACE 14,894 589
 CABG, MACE 21,851 1984
 MT, no MACE 5819 139
 PCI, no MACE 7204 72
 CABG, no MACE 17,774 482
MACE parameters
 MT (probability) 0.09 0.01
 OR for PCI 1.01 (0.35–2.86)a
 OR for CABG 3.80 (0.98–14.62)a
Table 4 Results of cost-effectiveness by trial (1-year) and lifetime time horizons. Mean and 95 % CI presented
Standard FFR Incremental ICER
Costs (£) QALYs Costs (£) QALYs Costs (£) QALYs (£/QALY)
Trial 7574 (6963–8443) 0.80 (0.76–0.84) 7686 (7141–8482) 0.82 (0.79–0.85) 112 (−129 to 357) 0.01 (−0.03 to 0.06) 7516
Lifetime 10,954 (9482–12,614) 6.30 (5.07–7.23) 11,087 (9652–12,699) 6.33 (5.09–7.25) 133 (−199 to 499) 0.03 (−0.21 to 0.28) 4290
Fig. 2 Cost-effectiveness plane displaying incremental costs vs. 
incremental QALYs
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apparent if one compares the variability of trial period 
costs in the raw vs. modelled results. FFR displayed raw 
cost-savings during the trial time horizon. Results, how-
ever, were very imprecise around a zero difference. By 
contrast, the decision analysis reduced the 95 % CI nearly 
six-fold and distilled a more clear direction of the distri-
bution. These adjusted results suggested more modest 
downstream cost savings that “recouped” part, but not 
all, of the intervention cost, leading to an overall mod-
est cost increase. As clinical trials becoming an increas-
ingly common source of evidence to assess the value for 
money of health interventions, analysts should consider 
such modelling practices.
Downstream cost savings were driven chiefly by abso-
lute, though non-significant, reductions in length of stay 
and health events such as revascularizations, rehospitali-
sations, MI and stroke. An improvement of the present 
analysis would be to model each important outcome sep-
arately, rather than as a composite. Composite outcomes 
make it difficult to attribute the appropriate individual 
cost and health-related utility tariffs. However, low event 
counts precluded a more detailed decision model that 
could characterise health events separately with statisti-
cal modelling and marginal prediction.
Inadequate information size was the greatest limitation 
of the FAMOUS pilot to inform cost-effectiveness. The 
primary objective of FAMOUS was to gather evidence on 
the FFR strategy in NSTEMI patients, and although the 
trial was designed to measure health outcomes at 1  year, 
it was not powered for these events. The resulting uncer-
tainty was apparent in costs of length of stay and events 
during the index year, with confidence intervals at least 
two/threefold greater than other cost categories. Low event 
counts precluded a more detailed decision model that 
could characterise downstream MI, rehospitalisation, and 
other events as functions of the patient management path-
way. Low information size also precludes a strong method 
to extend trial outcomes to a lifetime using the observed 
data. In order to estimate the wider lifetime impact of FFR, 
economic modelling would generally extend trial out-
comes. This is generally done by extrapolating survival and 
weighting it with an appropriate quality-of-life utility. How-
ever, FAMOUS pilot measured only two time points and 
observed 8 deaths making any extrapolation uninformative.
The strength of the analysis is also a potential limita-
tion. The decision analysis necessarily applies a structure 
to the decision problem. We believe the present struc-
ture to best represent the patient management pathway 
and the downstream important patient outcomes. The 
model structure attributes differences through these 
pathways. However, it may be the case that differences 
occur through an alternative pathway. Modelling, how-
ever, is unavoidable when extending outcomes beyond 
the trial horizon. Given the low information size and 
limited follow-up, the long-term model conditioned life 
expectancy on MACE. A common utility decrement was 
applied; however, those with MACE during the index 
year may return to quality of life similar to those who 
didn’t have MACE, at some point in the future. This 
would likely increase decision uncertainty by depressing 
the CEAC further towards 50  %. There may be differ-
ences in health events between FFR and standard angi-
ography-led management that do not present until well 
after the index year. At present, there is no indication of 
this but a larger planned future trial will measure this.
There is only one known study comparing economic 
outcomes for patients with NSTEMI, by Kent et  al. 
[21]. While their estimates of treatment following FFR 
were based on data of hypothetical treatment decisions, 
the present study uses actual decision data from the 
FAMOUS trial. The hypothetical results underestimated 
the actual reduction in primary revascularization fol-
lowing FFR (OR 0.88 vs 0.52, using raw unadjusted trial 
results). We found comparable incremental QALYs dur-
ing the index year to the Kent et al. study. We also found 
FFR led to cost-savings in similar areas, namely index 
treatment costs and downstream health event costs.
Consistently low mean ICERs over short- and long-
term horizons suggest FFR may represent a cost-effective 
resource allocation over standard angiography. The cost-
effectiveness of FFR, however, is met with considerable 
decision uncertainty. Uncertainty can be reduced with 
more information on long-term health events. Clinical 
trials are now a common source of evidence to assess 
the value for money of health interventions. Analysts 
should consider the benefits of a mixed model- and trial 
based-approach (or analysis) with decision and statistical 
modelling.
Fig. 3 Cost-effectiveness acceptability curves for the trial and lifetime 
time horizons
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Conclusions
FFR-guided management of NSTEMI may be a cost-
effective strategy over standard angiography, showing 
that more targeted invasive management can reduce 
healthcare resource costs without compromising 
patient outcomes. However, there still remains consid-
erable decision uncertainty which can be reduced with 
increased information size and additional long-term evi-
dence on major adverse cardiac events.
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